Disease · MONDO_0005388
primary biliary cholangitis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. primary biliary cholangitis. Diseases, record MONDO_0005388. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005388
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- Hanot syndrome, PBC, chronic non-suppurative destructive cholangitis, chronic nonsuppurative destructive cholangitis, primary Bilary cirrhosis (PBC), primary biliary cirrhosis
- Open Targets
Drugs51
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| URSODIOL | CHEMBL1551 | Small molecule | Approval | TTD | 36 | 35 | 35 | Drugs and targets |
| TAURURSODIOL | CHEMBL272427 | Small molecule | Approval | TTD | 31 | 30 | 2 | Drugs and targets |
| OBETICHOLIC ACID | CHEMBL566315 | Small molecule | Approval | TTD | 16 | 15 | 15 | Drugs and targets |
| FENOFIBRATE | CHEMBL672 | Small molecule | Phase 3 | ClinicalTrials.gov | 14 | 14 | 14 | Drugs and targets |
| BEZAFIBRATE | CHEMBL264374 | Small molecule | Phase 3 | ClinicalTrials.gov | 8 | 8 | 8 | Drugs and targets |
| SELADELPAR | CHEMBL230158 | Small molecule | Phase 3 | ClinicalTrials.gov | 8 | 8 | 8 | Drugs and targets |
| SAROGLITAZAR | CHEMBL4297530 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 1 | Drugs and targets |
| ELAFIBRANOR | CHEMBL3707395 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| LINERIXIBAT | CHEMBL2387408 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| BUDESONIDE | CHEMBL1370 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
1 to 10 of 51
See all 51 drugsTargets77
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| PPARA | Peroxisome proliferator-activated receptor | 5 | Peroxisome proliferator-activated receptor agonist; Peroxisome proliferator-activated receptor alpha agonist | Phase 3 | https://conductscience.org/library/genes/5465 | Drugs and targets |
| NR1H4 | Bile acid receptor | 4 | Bile acid receptor FXR agonist | Approval | https://conductscience.org/library/genes/9971 | Drugs and targets |
| PPARD | Peroxisome proliferator-activated receptor | 3 | Peroxisome proliferator-activated receptor agonist; Peroxisome proliferator-activated receptor delta agonist | Phase 3 | https://conductscience.org/library/genes/5467 | Drugs and targets |
| SLC10A2 | Ileal sodium/bile acid cotransporter | 3 | Ileal bile acid transporter inhibitor | Phase 3 | https://conductscience.org/library/genes/6555 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 2 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| OPRK1 | Kappa-type opioid receptor | 2 | Kappa opioid receptor agonist; Kappa opioid receptor partial agonist | Phase 2 | https://conductscience.org/library/genes/4986 | Drugs and targets |
| PPARG | Peroxisome proliferator-activated receptor | 2 | Peroxisome proliferator-activated receptor agonist; Peroxisome proliferator-activated receptor gamma agonist | Phase 3 | https://conductscience.org/library/genes/5468 | Drugs and targets |
| ACE | Angiotensin-converting enzyme | 1 | Angiotensin-converting enzyme inhibitor | Phase 2 | https://conductscience.org/library/genes/1636 | Drugs and targets |
| ADORA2A | Adenosine A2 receptor | 1 | Adenosine A2 receptor antagonist | Phase 2 | https://conductscience.org/library/genes/135 | Drugs and targets |
| ADORA2B | Adenosine A2 receptor | 1 | Adenosine A2 receptor antagonist | Phase 2 | https://conductscience.org/library/genes/136 | Drugs and targets |
1 to 10 of 77
See all 77 targetsTrials104
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 7 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02308111 | Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis | Phase 4 | 334 | 2023-03-09 | Liver Cirrhosis, Biliary | OBETICHOLIC ACID | Its record names the disease | ClinicalTrials.gov |
| NCT03602560 | ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA) | Phase 3 | 265 | 2022-05-31 | Primary Biliary Cholangitis | SELADELPAR | Its record names the disease | ClinicalTrials.gov |
| NCT04950127 | Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN) | Phase 3 | 238 | 2025-07-22 | Pruritus | LINERIXIBAT | Its record names the disease | ClinicalTrials.gov |
| NCT01473524 | Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis | Phase 3 | 217 | 2017-02-13 | Primary Biliary Cirrhosis | OBETICHOLIC ACID | Its record names the disease | ClinicalTrials.gov |
| NCT04620733 | RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA) | Phase 3 | 193 | 2024-07-25 | Primary Biliary Cholangitis | SELADELPAR | Its record names the disease | ClinicalTrials.gov |
| NCT00550862 | Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC) | Phase 2 | 165 | 2012-01-23 | Liver Cirrhosis, Biliary | OBETICHOLIC ACID, URSODIOL | Its record names the disease | ClinicalTrials.gov |
| NCT04526665 | Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) | Phase 3 | 161 | 2024-09-05 | Primary Biliary Cirrhosis | ELAFIBRANOR | Its record names the disease | ClinicalTrials.gov |
| NCT02966834 | Dose Response Study of GSK2330672 for the Treatment of Pruritus in Participants With Primary Biliary Cholangitis | Phase 2 | 147 | 2021-05-04 | Cholestasis | LINERIXIBAT | Its record names the disease | ClinicalTrials.gov |
| NCT02955602 | Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC) | Phase 2 | 119 | 2022-07-14 | Primary Biliary Cirrhosis | SELADELPAR | Its record names the disease | ClinicalTrials.gov |
| NCT03226067 | Study to Assess Safety & Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodiol. | Phase 2 | 111 | 2022-03-31 | Primary Biliary Cirrhosis | SETANAXIB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 104
See all 104 trialsComparisons in its trials10
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Obeticholic Acid vs Placebo: deaths from any cause | 16 of 168 | 12 of 166 | 334 | NCT02308111 | Trial comparisons |
| Obeticholic Acid vs Placebo: serious adverse events | 53 of 168 | 53 of 166 | 334 | NCT02308111 | Trial comparisons |
| Seladelpar vs Placebo: deaths from any cause | 0 of 128 | 0 of 65 | 193 | NCT04620733 | Trial comparisons |
| Seladelpar vs Placebo: serious adverse events | 9 of 128 | 4 of 65 | 193 | NCT04620733 | Trial comparisons |
| Elafibranor 80 mg vs Placebo: deaths from any cause | 2 of 108 | 0 of 53 | 161 | NCT04526665 | Trial comparisons |
| Elafibranor 80 mg vs Placebo: serious adverse events | 11 of 108 | 7 of 53 | 161 | NCT04526665 | Trial comparisons |
| Primary Treatment Phase vs Long-term Safety Extension Phase: deaths from any cause | 0 of 26 | 0 of 21 | 47 | NCT01865812 | Trial comparisons |
| Primary Treatment Phase vs Long-term Safety Extension Phase: serious adverse events | 1 of 26 | 5 of 21 | 47 | NCT01865812 | Trial comparisons |
| Obeticholic Acid (OCA) vs Placebo: deaths from any cause | 2 of 10 | 2 of 12 | 22 | NCT03633227 | Trial comparisons |
| Obeticholic Acid (OCA) vs Placebo: serious adverse events | 7 of 10 | 9 of 12 | 22 | NCT03633227 | Trial comparisons |
Papers from its trials78
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005388
GET https://conductscience.org/api/diseases/v1/MONDO_0005388/drugs?page=2